Awaiting a decision from overseas regulators on the chemotherapy booster Genasense for advanced melanoma, Genta Inc. is deciding its next steps in the U.S., after the FDA declared the product non-approvable for chronic lymphocytic leukemia. (BioWorld Today) Read More
